{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:02:44Z","timestamp":1761238964220,"version":"build-2065373602"},"reference-count":43,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Danish Medicines Research fund","award":["EMN-2017-00901"],"award-info":[{"award-number":["EMN-2017-00901"]}]},{"DOI":"10.13039\/501100006356","name":"University of Southern Denmark","doi-asserted-by":"publisher","award":["PhD grant"],"award-info":[{"award-number":["PhD grant"]}],"id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Enhancing treatment uptake for hepatitis C to achieve the elimination goals set by the World Health Organization could be achieved by reducing the treatment duration. The aim of this study was to compare the sustained virological response at week 12 (SVR12) after four weeks of glecaprevir\/pibrentasvir (GLE\/PIB) + ribavirin compared to eight weeks of GLE\/PIB and to estimate predictors for SVR12 with four weeks of treatment through a multicenter open label randomized controlled trial. Patients were randomized 2:1 (4 weeks:8 weeks) and stratified by genotype 3 and were treatment na\u00efve of all genotypes and without significant liver fibrosis. A total of 27 patients were analyzed for predictors for SVR12, including 15 from the first pilot phase of the study. In the \u2018modified intention to treat\u2019 group, 100% (7\/7) achieved cure after eight weeks and for patients treated for four weeks the SVR12 was 58.3% (7\/12). However, patients with a baseline viral load &lt;2 mill IU\/mL had 93% SVR12. The study closed prematurely due to the low number of included patients due to the COVID-19 pandemic. Our results suggest that viral load should be taken into account when considering trials of short course treatment.<\/jats:p>","DOI":"10.3390\/v14030614","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T03:36:23Z","timestamp":1647401783000},"page":"614","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Four Weeks Treatment with Glecaprevir\/Pibrentasvir + Ribavirin\u2014A Randomized Controlled Clinical Trial"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7864-1268","authenticated-orcid":false,"given":"Lone W.","family":"Madsen","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Odense University Hospital, 5000 Odense, Denmark"},{"name":"OPEN, Odense Patient Data Explorative Network, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Clinical Institute, University of Southern Denmark, 5000 Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peer B.","family":"Christensen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Clinical Institute, University of Southern Denmark, 5000 Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne F.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit T.","family":"R\u00f8ge","sequence":"additional","affiliation":[{"name":"Unit for Infectious Diseases, Department of Medicine, Sygehus Lilleb\u00e6lt, 6000 Kolding, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8156-7177","authenticated-orcid":false,"given":"Dorte K.","family":"Holm","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Dr\u00f6se","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Clinical Institute, University of Southern Denmark, 5000 Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"\u00d8vrehus","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Clinical Institute, University of Southern Denmark, 5000 Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Blach, S., Terrault, N.A., Tacke, F., Gamkrelidze, I., Craxi, A., Tanaka, J., Waked, I., Dore, G.J., Abbas, Z., and Abdallah, A.R. (2022). Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study. Lancet Gastroenterol. Hepatol.","DOI":"10.1016\/S2468-1253(21)00472-6"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S2468-1253(16)30075-9","article-title":"Hepatitis C treatment as prevention: Evidence, feasibility, and challenges","volume":"1","author":"Hajarizadeh","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","unstructured":"World Health Organization (2016). Global Health Sector Strategy on Viral Hepatitis 2016\u20132021. Towards Ending Viral Hepatitis, World Health Organization. Available online: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf;jsessionid=4A31033A10540FAFD7C0418369431855?sequence=1."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/liv.14779","article-title":"Progress towards hepatitis C virus elimination in high-income countries: An updated analysis","volume":"41","author":"Gamkrelidze","year":"2021","journal-title":"Liver Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/liv.14324","article-title":"Global timing of hepatitis C virus elimination in high-income countries","volume":"40","author":"Razavi","year":"2020","journal-title":"Liver Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugpo.2017.07.006","article-title":"Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade","volume":"47","author":"Scott","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"ref_7","unstructured":"Clinton Health Access Initiative (2021). HCV Market Intelligence Report 2021 and Preliminary Market Insights, Clinton Health Access Initiative."},{"key":"ref_8","unstructured":"World Health Organization (2020). Accelerating Access to Hepatitis C Diagnostics and Treatment, World Health Organization."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: A modelling study","volume":"4","author":"Trickey","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1093\/cid\/ciz1089","article-title":"Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy","volume":"71","author":"Cunningham","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12072-015-9680-7","article-title":"High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study","volume":"10","author":"Petersen","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.12688\/wellcomeopenres.16594.2","article-title":"Strategic treatment optimization for HCV (STOPHCV1): A randomised controlled trial of ultrashort duration therapy for chronic hepatitis C","volume":"6","author":"Cooke","year":"2021","journal-title":"Wellcome Open Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/j.gastro.2016.05.021","article-title":"Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3\/4A Protease Inhibitor GS-9857 in Treatment-Naive or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.7326\/M15-0642","article-title":"Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial","volume":"163","author":"Kohli","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2468-1253(16)30015-2","article-title":"Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: A phase 2, open-label, proof-of-concept study","volume":"1","author":"Lau","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.28877","article-title":"Short-duration treatment with elbasvir\/grazoprevir and sofosbuvir for hepatitis C: A randomized trial","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2017.11.031","article-title":"Four weeks of ledipasvir\/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial","volume":"68","author":"Ovrehus","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/liv.13335","article-title":"Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)","volume":"37","author":"Sulkowski","year":"2017","journal-title":"Liver Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/liv.14991","article-title":"Inferior cure rate in pilot study of 4-week glecaprevir\/pibrentasvir treatment with or without ribavirin of chronic hepatitis C","volume":"41","author":"Madsen","year":"2021","journal-title":"Liver Int."},{"key":"ref_20","unstructured":"World Health Organization (2018). Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection, World Health Organization. Available online: https:\/\/www.who.int\/publications-detail-redirect\/9789241550345."},{"key":"ref_21","unstructured":"OPEN (2021, September 10). Open Patient Data Explorative Network (OPEN). Available online: https:\/\/www.sdu.dk\/da\/ki\/open."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.3748\/wjg.v22.i33.7604","article-title":"Dried blood spots, valid screening for viral hepatitis and human immunodeficiency virus in real-life","volume":"22","author":"Staugaard","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.3748\/wjg.v23.i26.4759","article-title":"Eight-week ledipasvir\/sofosbuvir in non-cirrhotic, treatment-na\u00efve hepatitis C genotype-1 patients with hepatitis C virus-RNA <6 million: Single center, real world effectiveness and safety","volume":"23","author":"Latt","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2021.04.056","article-title":"Sofosbuvir\/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection","volume":"75","author":"Matthews","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17820","DOI":"10.1038\/s41598-020-74568-x","article-title":"Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: A Pilot study","volume":"10","author":"Etzion","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.drup.2013.06.001","article-title":"Containing \u201cThe Great Houdini\u201d of viruses: Combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C","volume":"16","author":"Frelin","year":"2013","journal-title":"Drug Resist. Updates"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrgastro.2015.97","article-title":"Modelling hepatitis C therapy--predicting effects of treatment","volume":"12","author":"Perelson","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1053\/j.gastro.2008.07.023","article-title":"Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors","volume":"135","author":"Liang","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1478-3231.2008.01936.x","article-title":"What future for ribavirin?","volume":"29","author":"Shiffman","year":"2009","journal-title":"Liver Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","article-title":"Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection","volume":"37","author":"Feld","year":"2017","journal-title":"Liver Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2015.01.004","article-title":"A path to eradication of hepatitis C in low- and middle-income countries","volume":"119","author":"Graham","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMsr1912628","article-title":"Screening and Treatment Program to Eliminate Hepatitis C in Egypt","volume":"382","author":"Waked","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1016\/j.jhep.2016.07.035","article-title":"The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control","volume":"65","author":"Bukh","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jhep.2019.07.025","article-title":"Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C","volume":"71","author":"Childs","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/hep.30225","article-title":"Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r","volume":"69","author":"Fourati","year":"2019","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e0075521","DOI":"10.1128\/MRA.00755-21","article-title":"Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment","volume":"10","author":"Pedersen","year":"2021","journal-title":"Microbiol. Resour. Announc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.14309\/ajg.0000000000001332","article-title":"High Sustained Virologic Response Rates of Glecaprevir\/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence","volume":"116","author":"Zamor","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S2468-1253(21)00077-7","article-title":"Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): A prospective cohort study","volume":"6","author":"Hajarizadeh","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hep.31003","article-title":"Short-Duration Pan-Genotypic Therapy With Glecaprevir\/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection","volume":"72","author":"Martinello","year":"2020","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M20-1468","article-title":"Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study","volume":"174","author":"Durand","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","article-title":"Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients","volume":"380","author":"Woolley","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/3\/614\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:37:15Z","timestamp":1760135835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/3\/614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["v14030614"],"URL":"https:\/\/doi.org\/10.3390\/v14030614","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2022,3,16]]}}}